OBJECTIVE: Lynch syndrome is a heritable, cancer susceptibility syndrome. This study aims to review current and emerging trends in the identification of Lynch syndrome in the endometrial cancer patient population. METHODS: We performed a comprehensive review of past and present screening algorithms for Lynch syndrome, including a review of the utility of both the Amsterdam criteria and Bethesda guidelines. Because non-colon cancers have historically not been the focus of Lynch syndrome research, current literature is ripe with questions regarding screening among this patient population. Low BMI, age less than 50, positive family history and pathologic features have all been identified as risk factors in endometrial cancer patients who might benefit from Lynch screening. Additionally, based on experience at our own institution we offer a feasible screening algorithm for these patients. RESULTS: A comprehensive review of the data demonstrated that immunohistochemistry is becoming an efficient, inexpensive way to screen tumors at risk for mismatch repair deficiency. The sensitivity and specificity of immunohistochemistry for predicting Lynch syndrome approaches 100%. Ideally, prospective screening of all endometrial cancer patients with IHC is a feasible, cost-efficient way to detect Lynch in this patient population given the limitations of using personal/family history of malignancy as well as pathologic risk factors. CONCLUSION: It is imperative that clinicians be mindful of the risk of Lynch syndrome in women with endometrial cancer. Given the opportunity for colon cancer screening and prevention strategies to be initiated, the identification of probands with endometrial cancer as a result of Lynch syndrome will lead to a reduction in morbidity and mortality for these patients and their families.
OBJECTIVE:Lynch syndrome is a heritable, cancer susceptibility syndrome. This study aims to review current and emerging trends in the identification of Lynch syndrome in the endometrial cancerpatient population. METHODS: We performed a comprehensive review of past and present screening algorithms for Lynch syndrome, including a review of the utility of both the Amsterdam criteria and Bethesda guidelines. Because non-colon cancers have historically not been the focus of Lynch syndrome research, current literature is ripe with questions regarding screening among this patient population. Low BMI, age less than 50, positive family history and pathologic features have all been identified as risk factors in endometrial cancerpatients who might benefit from Lynch screening. Additionally, based on experience at our own institution we offer a feasible screening algorithm for these patients. RESULTS: A comprehensive review of the data demonstrated that immunohistochemistry is becoming an efficient, inexpensive way to screen tumors at risk for mismatch repair deficiency. The sensitivity and specificity of immunohistochemistry for predicting Lynch syndrome approaches 100%. Ideally, prospective screening of all endometrial cancerpatients with IHC is a feasible, cost-efficient way to detect Lynch in this patient population given the limitations of using personal/family history of malignancy as well as pathologic risk factors. CONCLUSION: It is imperative that clinicians be mindful of the risk of Lynch syndrome in women with endometrial cancer. Given the opportunity for colon cancer screening and prevention strategies to be initiated, the identification of probands with endometrial cancer as a result of Lynch syndrome will lead to a reduction in morbidity and mortality for these patients and their families.
Authors: Paul J Goodfellow; Barbara M Buttin; Thomas J Herzog; Janet S Rader; Randall K Gibb; Elizabeth Swisher; Katherine Look; Ken C Walls; Ming-Yu Fan; David G Mutch Journal: Proc Natl Acad Sci U S A Date: 2003-05-05 Impact factor: 11.205
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: H F Vasen; P Watson; J P Mecklin; J R Jass; J S Green; T Nomizu; H Müller; H T Lynch Journal: Anticancer Res Date: 1994 Jul-Aug Impact factor: 2.480
Authors: Jinru Shia; Nathan A Ellis; Philip B Paty; Garrett M Nash; Jing Qin; Kenneth Offit; Xin-Min Zhang; Arnold J Markowitz; Khedoudja Nafa; Jose G Guillem; W Douglas Wong; William L Gerald; David S Klimstra Journal: Am J Surg Pathol Date: 2003-11 Impact factor: 6.394
Authors: J G Herman; A Umar; K Polyak; J R Graff; N Ahuja; J P Issa; S Markowitz; J K Willson; S R Hamilton; K W Kinzler; M F Kane; R D Kolodner; B Vogelstein; T A Kunkel; S B Baylin Journal: Proc Natl Acad Sci U S A Date: 1998-06-09 Impact factor: 11.205
Authors: Yvonne M C Hendriks; Anja Wagner; Hans Morreau; Fred Menko; Astrid Stormorken; Franz Quehenberger; Lodewijk Sandkuijl; Pal Møller; Maurizio Genuardi; Hans Van Houwelingen; Carli Tops; Marjo Van Puijenbroek; Paul Verkuijlen; Gemma Kenter; Anneke Van Mil; Hanne Meijers-Heijboer; Gita B Tan; Martijn H Breuning; Riccardo Fodde; Juul Th Wijnen; Annette H J T Bröcker-Vriends; Hans Vasen Journal: Gastroenterology Date: 2004-07 Impact factor: 22.682
Authors: Barbara M Buttin; Matthew A Powell; David G Mutch; Sheri A Babb; Phyllis C Huettner; Tina Bocker Edmonston; Thomas J Herzog; Janet S Rader; Randall K Gibb; Alison J Whelan; Paul J Goodfellow Journal: Am J Hum Genet Date: 2004-04-19 Impact factor: 11.025
Authors: Shannon N Westin; Robin A Lacour; Diana L Urbauer; Rajyalakshmi Luthra; Diane C Bodurka; Karen H Lu; Russell R Broaddus Journal: J Clin Oncol Date: 2008-11-10 Impact factor: 44.544
Authors: Amanda S Bruegl; Bojana Djordjevic; Diana L Urbauer; Shannon N Westin; Pamela T Soliman; Karen H Lu; Rajyalakshmi Luthra; Russell R Broaddus Journal: Curr Pharm Des Date: 2014 Impact factor: 3.116
Authors: Daniel D Buchanan; Yen Y Tan; Michael D Walsh; Mark Clendenning; Alexander M Metcalf; Kaltin Ferguson; Sven T Arnold; Bryony A Thompson; Felicity A Lose; Michael T Parsons; Rhiannon J Walters; Sally-Ann Pearson; Margaret Cummings; Martin K Oehler; Penelope B Blomfield; Michael A Quinn; Judy A Kirk; Colin J Stewart; Andreas Obermair; Joanne P Young; Penelope M Webb; Amanda B Spurdle Journal: J Clin Oncol Date: 2013-12-09 Impact factor: 44.544
Authors: Ji-Hyun Lee; Deborah Cragun; Zachary Thompson; Domenico Coppola; Santo V Nicosia; Mohammad Akbari; Shiyu Zhang; John McLaughlin; Steven Narod; Joellen Schildkraut; Thomas A Sellers; Tuya Pal Journal: Genet Test Mol Biomarkers Date: 2014-03-04